News
4h
Capital Market on MSNAurobindo Pharma gets UK MHRA approval for neutropenia treatment drug DyrupegDyrupeg contains the active substance pegfilgrastim and is a biological medicine. It is a 'biosimilar medicine'; this means ...
Player grades: Thunder devour Nuggets in 125-93 Game 7 win to advance to WCF Photos: Best images from Thunder's 125-93 Game 7 win over Nuggets How to watch Nuggets vs. Thunder Game 7 today: Time, TV ...
Player grades: Thunder embarrassed by Timberwolves in 143-101 Game 3 loss Photos: Best images from Thunder's 143-101 Game 3 loss to Timberwolves How to watch Thunder vs. Timberwolves Game 3 today: ...
Adding subcutaneous daratumumab to KRd increased the likelihood of MRD negativity in patients with newly diagnosed MM, regardless of transplant eligibility.
Learn more about some of the signs and symptoms of neutropenia in newborns and why infants with HDFN may be at greater risk.
Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.
Early results from the MagnetisMM-6 trial reveal promising efficacy of elranatamab, daratumumab, and lenalidomide in treating ...
The IsKia trial reveals that isatuximab enhances MRD negativity in newly diagnosed multiple myeloma, especially in high-risk ...
The FDA has approved tafasitamab in combination with lenalidomide and rituximab for adults with relapsed/refractory ...
Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded ...
Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant
Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...
Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results